- World rank, all time
- #37,008 of 42,892
- Rank in Sweden
- #260 of 286
- Research works
- 123 ▼ 13% vs 2013–17
- Citations
- 3.1k 25.5 per fractional work
- Top-10% rate
- 21.3% record average 16.5%
- Open access
- 46% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.4×. Every wedge is a field page.
- Medicine 3.4×
- Economics, Econometrics and Finance 2.1×
- Biochemistry, Genetics and Molecular Biology 2.0×
- Immunology and Microbiology 1.3×
- Arts and Humanities 0.9×
- Earth and Planetary Sciences 0.7×
- Health Professions 0.6×
- Social Sciences 0.6×
- Neuroscience 0.6×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Chemistry 0.1×
- Engineering 0.1×
- Psychology 0.1×
- Computer Science 0.1×
- Environmental Science 0.1×
- Agricultural and Biological Sciences 0.0×
Who are the top researchers at Pfizer (Sweden)?
Ranked on the composite score, Maria Kołtowska‐Häggström, Fredrik Nilsson and Rickard Sandin lead among researchers whose main affiliation is Pfizer (Sweden).
- 1 Maria Kołtowska‐Häggström Sweden · #684,318 worldwide 52 citations · 16 works
- 2 Fredrik Nilsson Sweden · #936,969 worldwide 22 citations · 35 works
- 3 Rickard Sandin Sweden · #1,155,713 worldwide 27 citations · 17 works
Which keywords describe research at Pfizer (Sweden)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Immunotherapy, Breast Cancer, Metastatic Breast Cancer, Clinical Trials, Pandemic, CDK4/6 Inhibitors and Palbociclib.
- Qualitative Research
- Genomic Profiling
- Targeted Therapy
- Respiratory Syncytial Virus
- Pathogenesis
- Human Metapneumovirus
- Chemotherapy
- Vaccine Development
- Therapy
- Pathophysiology
- Discourse Analysis
- Clinical Characteristics
- Metastatic
- Clinical Guidelines
- Prognostic Factors
- ACE2 Receptor
- Palbociclib
- Clinical Trials
- Metastatic Breast Cancer
- Immunotherapy
- Epidemiology
- Breast Cancer
- Pandemic
- CDK4/6 Inhibitors
- Treatment
- Genetic Mutations
- SARS-CoV-2
- Immune Response
- Clinical Practice Guidelines
- Cytokine Storm
- Molecular Characterization
- Renal Cell Carcinoma
- Thrombosis
- Viral Infections
- Diagnosis Criteria
- International Myeloma Working Group
- Proteasome Inhibitors
- Social Sciences
- Catheter Ablation
- Methodology
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology5▲ 4.2×23 topics
- Immunotherapy2▲ 11×7 topics
- Breast Cancer2▲ 32×6 topics
- Metastatic Breast Cancer2▲ 123×2 topics
- Pandemic2▲ 6.4×3 topics
- Clinical Trials2▲ 9.6×7 topics
- CDK4/6 Inhibitors2▲ 244×1 topic
- Palbociclib2▲ 244×1 topic
- Treatment2▲ 5.1×5 topics
- ACE2 Receptor2▲ 23×2 topics
- Genetic Mutations2▲ 13×4 topics
- Prognostic Factors2▲ 13×3 topics
- SARS-CoV-22▲ 17×2 topics
- Clinical Guidelines2▲ 17×3 topics
- Immune Response2▲ 8.8×6 topics
- Metastatic1▲ 73×2 topics
- Clinical Practice Guidelines1▲ 7.5×5 topics
- Clinical Characteristics1▲ 31×2 topics
- Cytokine Storm1▲ 35×1 topic
- Discourse Analysis1▲ 15×3 topics
- Molecular Characterization1▲ 22×2 topics
- Pathophysiology1▲ 13×2 topics
- Renal Cell Carcinoma1▲ 113×1 topic
- Therapy1▲ 19×1 topic
- Thrombosis1▲ 13×1 topic
- Vaccine Development1▲ 15×2 topics
- Viral Infections1▲ 70×2 topics
- Chemotherapy1▲ 5.2×6 topics
- Diagnosis Criteria1▲ 100×1 topic
- Human Metapneumovirus1▲ 79×1 topic
- International Myeloma Working Group1▲ 100×1 topic
- Pathogenesis1▲ 6.9×5 topics
- Proteasome Inhibitors1▲ 51×2 topics
- Respiratory Syncytial Virus1▲ 79×1 topic
- Social Sciences1▲ 25×2 topics
- Targeted Therapy1▲ 16×4 topics
- Catheter Ablation1▲ 28×2 topics
- Genomic Profiling1▲ 32×2 topics
- Methodology1▲ 68×1 topic
- Qualitative Research1▲ 3.7×1 topic
Which research topics does Pfizer (Sweden) publish most on?
By volume in 2022–2025: Advanced Breast Cancer Therapies, COVID-19 Clinical Research Studies, Renal cell carcinoma treatment and Respiratory viral infections research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 2 COVID-19 Clinical Research Studies Infectious Diseases 1 works
- 3 Renal cell carcinoma treatment Pulmonary and Respiratory Medicine 1 works
- 4 Respiratory viral infections research Epidemiology 1 works
- 5 Multiple Myeloma Research and Treatments Hematology 1 works
- 6 Social and Educational Sciences Education 1 works
- 7 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
- 8 Migraine and Headache Studies Psychiatry and Mental health 1 works
- 9 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 1 works
- 10 SARS-CoV-2 and COVID-19 Research Infectious Diseases 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Pfizer (Sweden)'s research output changed?
Output in 2018–2022 was 13% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Sollentuna
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.